Ginkgo Bioworks Q1 Revenue Plummets 49% to $19.5M Amid Continued Losses
DNA sits 59% above its 52-week low of $5.37.
Summary
Ginkgo Bioworks reported its first-quarter 2026 results, revealing a significant 49% year-over-year decline in revenue to $19.5 million. The company also posted a GAAP net loss from continuing operations of $(76.1) million and an Adjusted EBITDA loss of $(42.3) million. This earnings report provides the first look at the company's financial performance following the strategic divestiture of its Biosecurity business on April 3, 2026, a move previously outlined in its last 10-K. The substantial revenue contraction in its continuing operations is a material concern for investors, despite a slight narrowing of losses. Traders will be closely watching for signs of improved revenue growth and reduced cash burn, especially given the reiterated full-year cash burn guidance of $(150) million to $(125) million.
At the time of this announcement, DNA was trading at $8.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $633.2M. The 52-week trading range was $5.37 to $17.58. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.